Israel - English - Ministry of Health

megapharm ltd - cyclophosphamide - powder for solution for injection - cyclophosphamide 500 mg/vial - cyclophosphamide - cyclophosphamide - malignant diseases: cycophosphamide although effective alone in susceptible melignancies is more frequently used concurrently or sequentially with other antineoplastic drugs. the following malignancies are often susceptible. cycophosphamide treatment: 1) malignant lymphomas (stages iii and iv of the ann arbor staging system) hodgkin`s disease lymphocytic lymphoma (nodular or diffuse) mixed-cell type lymphoma histiocytic lymphoma burkitt`s lymphoma. 2) multiple myeloma. 3) leukemias: chronic lymphocytic leukemia chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis) acute myelogenous and monocytic leukemia acute lymphoblastic (stemcell) leukemia in children. 4) mycosis fungoides (advenced disease). 5) neuroblastoma (disseminated disease). 6) adenocarcinoma of the ovary. 7) retinoblastoma. 8) carcinoma of the breast. nonmallgnant disease biopsy proven "minimal change" nephrotic syndrome in children whose disease fails to respond adequately to another treatment. severe cases of systemic lupus erythematos as which did not respond to other treatment especially with nephritis

Israel - English - Ministry of Health

megapharm ltd - cyclophosphamide - powder for solution for injection - cyclophosphamide 1 g/vial - cyclophosphamide - cyclophosphamide - malignant diseases: cycophosphamide although effective alone in susceptible melignancies is more frequently used concurrently or sequentially with other antineoplastic drugs. the following malignancies are often susceptible. cycophosphamide treatment: 1) malignant lymphomas (stages iii and iv of the ann arbor staging system) hodgkin`s disease lymphocytic lymphoma (nodular or diffuse) mixed-cell type lymphoma histiocytic lymphoma burkitt`s lymphoma. 2) multiple myeloma. 3) leukemias: chronic lymphocytic leukemia chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis) acute myelogenous and monocytic leukemia acute lymphoblastic (stemcell) leukemia in children. 4) mycosis fungoides (advenced disease). 5) neuroblastoma (disseminated disease). 6) adenocarcinoma of the ovary. 7) retinoblastoma. 8) carcinoma of the breast. nonmallgnant disease biopsy proven "minimal change" nephrotic syndrome in children whose disease fails to respond adequately to another treatment. severe cases of systemic lupus erythematos as which did not respond to other treatment especially with nephritis

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - cyclophosphamide monohydrate - powder for solution for injection - 2gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - cyclophosphamide monohydrate - powder for solution for injection - 1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - cyclophosphamide monohydrate - powder for solution for injection - 500mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

hankook korus pharm co. - cyclophosphamide - powder for solution for injection - 500mg

Ireland - English - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - cyclophosphamide monohydrate - coated tablets - 50 milligram - cyclophosphamide

Ireland - English - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - cyclophosphamide - pdr for soln for injection - 500 milligram - cyclophosphamide

Ireland - English - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - cyclophosphamide - pdr for soln for injection - 1000 milligram - cyclophosphamide

Singapore - English - HSA (Health Sciences Authority)

shoei universal corporation pte ltd - cyclophosphamide - injection, powder, for solution - 1 g/vial - cyclophosphamide 1 g/vial